Wang Huiwei, Hou Suchun, Kang Xiaojing, Yu Chen, Yang Bin, Shi Yuling, Li Fuqiu, Li Wei, Gu Jun, Lei Mingjun, Lin Youkun, Wang Gang, Jin Hongzhong, Liu Xiaoming
Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, No. 1 Haiyuan 1 Rd, Futian District, Shenzhen, 518053, Guangdong, China.
Department of Dermatology, Shenzhen University General Hospital, No. 1098 Xue Yuan Avenue, Xi Li University Town, Nanshan District, Shenzhen, 518055, Guangdong, China.
Sci Rep. 2025 Apr 1;15(1):11158. doi: 10.1038/s41598-025-94505-0.
This study aims to investigate the causal relationship between Body Mass Index (BMI) and the severity of Psoriasis (PsO) using bidirectional Mendelian Randomization (MR) and regression analyses. We conducted a multicenter study which combined bidirectional MR analyses with regression analyses. The MR analyses included 366,776 individuals from the largest up-to-date published BMI Genome-Wide Association Study (GWAS) data. Regression analyses were performed on 1,979 patients with psoriasis from 12 participating centers (from October 31, 2019, to May 31, 2022). We assessed the impact of BMI on PsO severity using odds ratios (ORs) and regression coefficients for three key measures: the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI). Two independent MR analyses revealed a significant causal association between BMI and PsO development. The first MR1 analysis showed that an increased BMI is significantly associated with a higher risk of psoriasis, with odds ratios of 2.28 (95% CI 1.33-3.92; p = 0.003). A subsequent MR2 analysis yielded consistent results, presenting an odds ratio of 2.37 (95% CI 1.16-4.85; p = 0.018) using the inverse-variance weighted method. Logistic regression showed that for every 1-unit increase in BMI (unadjusted covariates), the risk of severe psoriasis (PASI ≥ 10, BSA ≥ 10%, DLQI ≥ 10) increased by 6%, 6%, and 3%, respectively. Linear regression analysis revealed that each unit increase in BMI (not standardised) was associated with an increase of 0.25 units in the mean PASI score (p < 0.001), 0.34 units in the BSA score (p = 0.001), and 0.14 units in the DLQI score (95% CI 0.05-0.23; p = 0.001). From both the genetic and clinical severity assessment perspectives, it has been verified that abnormal weight gain is correlated with the severity of the condition in psoriasis patients. Clinicians should prioritize weight management and nutritional balance in the management of psoriatic disease. Clinicaltrials.gov: ChiCTR1900024852, date of registration: 2019-07-31.
本研究旨在使用双向孟德尔随机化（MR）和回归分析，探讨体重指数（BMI）与银屑病（PsO）严重程度之间的因果关系。我们开展了一项多中心研究，将双向MR分析与回归分析相结合。MR分析纳入了来自已发表的最新、最大规模BMI全基因组关联研究（GWAS）数据中的366,776名个体。对来自12个参与中心的1979例银屑病患者（2019年10月31日至2022年5月31日）进行了回归分析。我们使用比值比（OR）和回归系数，评估BMI对PsO严重程度的影响，这三个关键指标分别为：银屑病面积和严重程度指数（PASI）、体表面积（BSA）以及皮肤病生活质量指数（DLQI）。两项独立的MR分析揭示了BMI与PsO发生之间存在显著的因果关联。首次MR1分析显示，BMI升高与银屑病风险显著增加相关，比值比为2.28（95%CI 1.33 - 3.92；p = 0.003）。随后的MR2分析得出了一致的结果，采用逆方差加权法得出的比值比为2.37（95%CI 1.16 - 4.85；p = 0.018）。逻辑回归显示，BMI每增加1个单位（未调整协变量），重度银屑病（PASI≥10、BSA≥10%、DLQI≥10）的风险分别增加6%、6%和3%。线性回归分析显示，BMI每增加1个单位（未标准化），平均PASI评分增加0.25个单位（p < 0.001），BSA评分增加0.34个单位（p = 0.001），DLQI评分增加0.14个单位（95%CI 0.05 - 0.23；p = 0.001）。从遗传和临床严重程度评估的角度来看，体重异常增加与银屑病患者病情严重程度相关已得到验证。临床医生在银屑病疾病管理中应优先考虑体重管理和营养平衡。Clinicaltrials.gov：ChiCTR1900024852，注册日期：
